Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTE5ITK)

• DTT Name: Cancer/testis antigen 1 (NY-ESO-1) DTT Info
• Gene Name: CTAG1A

Molecule-Related Drug & Molecule List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CDX-1401	DMCGNJ6	Ovarian cancer	2C73	Phase 2	[1]
Anti-NY-ESO-1 CAR-T cells	DM26VCZ	Esophageal cancer	2B70	Phase 1/2	[2]
CV-9201	DMCPZYT	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[3]
GSK-2241658A	DM5VS7B	Melanoma	2C30	Phase 1	[4]
GSK3845097	DM1UQ4Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
GSK3901961	DMN4I7P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
NY-ESO-1 vaccine	DM0EKUQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[7]

References

• [1] National Cancer Institute Drug Dictionary (drug id 651880).
• [2] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [3] National Cancer Institute Drug Dictionary (drug id 648549).
• [4] ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [6] Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002 December 15; 110(12): 1813-1822.
• [7] Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.